In his initial confirmation testimony, former pharma executive and HHS secretary nominee Alex Azar said he would stop drug manufacturers from gaming the system and blocking generic competitors from the market.
The FDA's new guidance aims to make it easier for generic firms to plan how they can copy complex drugs like epinephrine auto-injectors, which should ultimately lower pharmaceutical prices.
Connecticut and 45 other states are seeking to expand a federal antitrust lawsuit against generic-drug makers to include more manufacturers and medications, as well as senior executives at two companies.
Chip Davis, the president and CEO of the Association for Accessible Medicines, talks about the need for more competition to bring down healthcare costs.
Making actual generic drug acquisition costs available to third-party payers would empower health plans to negotiate lower rates and essentially level the playing field in a pharmaceutical supply chain that's shrouded in secrecy, according to a new paper.
Sanofi's commitment to limit prices to the rise in the National Health Expenditure Data Accounts—estimated to be 5.6% annually from 2016 to 2025—is not enough, healthcare experts said.
The rising prices of branded drugs are affecting consumers, providers and payers alike, which have seen drug prices jump 18% every year since 2010.
A bipartisan pair of congressmen on Thursday proposed a bill in the U.S. House of Representatives to try to prevent drugmakers from blocking generic and biosimilar competitors.
Angered by skyrocketing drug prices, a pair of senators on Wednesday urged Congress to block companies from cornering the market on old, off-patent drugs.
The generic drug industry, responding to public anger over big price hikes for some generic products, is calling for action on a bipartisan Senate bill it says would increase the number of cheaper generic drugs and reduce U.S. drug spending.
Clinton proposes new enforcement mechanisms, including having the government buy and provide alternative therapies to patients, allowing temporary importation of lower-priced drugs from foreign countries and fining drug companies that excessively raise prices.
Mylan made a somewhat surprising announcement Monday that it would launch a generic version of its EpiPen in several weeks and sell it for half the list price of its branded product. So where have those plans been for the decade it's been selling the product?